For the first time, a new drug given along with a cholesterol-lowering statin medicine has proved able to shrink plaque that is clogging arteries, potentially giving a way to undo some of the damage ...

The government’s approval of a new drug to lower cholesterol could mean billions of dollars for Thousand Oaks biotech giant Amgen — and spark a new round of debate over the thousands of dollars it ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...

An error has occurred. Please try again. With a The Portland Press Herald subscription, you can gift 5 articles each month. It looks like you do not have any active ...

The action by NICE highlights discussion on both sides of the Atlantic about the cost of PCSK9 inhibitors, which lower LDL cholesterol. The cholesterol drug evolocumab, being marketed by Amgen as ...

Repatha is the second in a new class of drugs called PCSK9 inhibitors to win FDA approval The drug is a second line of treatment for those who can't take or don't respond to widely used statins for ...

The first rigorous test of an expensive new drug that substantially lowers cholesterol levels found it significantly reduced the chance a high-risk patient would have a heart attack or stroke. These ...

Getting your Trinity Audio player ready... NEW ORLEANS — For the first time, a new drug given along with a cholesterol-lowering statin medicine has proved able to shrink plaque that is clogging ...

The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease. Last month the FDA ...

NEW ORLEANS >> For the first time, a new drug given along with a cholesterol-lowering statin medicine has proved able to shrink plaque that is clogging arteries, potentially giving a way to undo some ...